| 2024-12-11 | -79.9% | legal | SEC EDGAR | CLRB 8-K: 2.05, 7.01, 8.01 (SEC Filing) |
| 2024-12-11 | -79.9% | news | Yahoo Finance | Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Yahoo Finance |
| 2024-12-10 | -77.5% | news | Seeking Alpha | Cellectar stock plunges 50% post-market on restructuring news |
| 2025-06-04 | +46.9% | legal | Yahoo Finance | What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained - Yahoo Finance |
| 2024-01-08 | +33.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2024-01-08 | +33.4% | news | Seeking Alpha | Cellectar Biosciences stock jumps on radiotherapy data - Seeking Alpha |
| 2025-10-07 | -22.8% | expansion | Seeking Alpha | Cellectar Biosciences enters into agreements to raise $5.8M |
| 2025-10-07 | -22.8% | news | Stocktwits | Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - Stocktwits |
| 2025-10-07 | -22.8% | expansion | Yahoo Finance | Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million - Yahoo Finance |
| 2025-06-05 | -22.3% | expansion | Seeking Alpha | Cellectar Biosciences enters into common stock agreements to raise $2.5 million |
| 2025-06-05 | -22.3% | legal | SEC EDGAR | CLRB 8-K: 1.01, 3.02, 3.03, 7.01 (SEC Filing) |
| 2024-07-23 | -20.1% | legal | Seeking Alpha | Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones |
| 2024-07-23 | -20.1% | legal | SEC EDGAR | CLRB 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2025-03-17 | +19.1% | legal | SEC EDGAR | CLRB 8-K: 5.02, 5.03 (SEC Filing) |
| 2025-06-11 | +18.8% | news | Stock Titan | Breakthrough: New Drug Doubles Survival Time in Aggressive Childhood Brain Cancer Trial - Stock Titan |
| 2023-06-13 | +16.6% | legal | SEC EDGAR | CLRB 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-06-18 | -16.6% | news | Seeking Alpha | Cellectar Biosciences announces one-for-thirty reverse stock split |
| 2025-06-18 | -16.6% | legal | SEC EDGAR | CLRB 8-K: 8.01 and (SEC Filing) |
| 2022-03-21 | +15.5% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2025-11-13 | -15.5% | expansion | Seeking Alpha | Cellectar signals 2027 global launch for iopofosine as regulatory momentum accelerates |
| 2025-11-13 | -15.5% | earnings | Seeking Alpha | Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript |
| 2025-11-13 | -15.5% | earnings | Seeking Alpha | Cellectar Biosciences GAAP EPS of -$1.41 beats by $1.12 |
| 2025-11-13 | -15.5% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2024-06-14 | -14.5% | legal | SEC EDGAR | CLRB 8-K: 5.02, 5.07 (SEC Filing) |
| 2024-11-18 | -14.2% | earnings | Seeking Alpha | Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript |
| 2024-11-18 | -14.2% | earnings | Seeking Alpha | Cellectar Biosciences GAAP EPS of -$0.40 misses by $0.03 |
| 2024-11-18 | -14.2% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2026-01-09 | +14.0% | news | Stock Titan | Cancer-focused biotech maps 2026 push in blood and breast tumors - Stock Titan |
| 2024-02-02 | -13.7% | legal | SEC EDGAR | CLRB 8-K: 8.01 (SEC Filing) |
| 2023-06-14 | +13.2% | legal | SEC EDGAR | CLRB 8-K: 8.01 (SEC Filing) |
| 2025-06-24 | -12.9% | legal | Stock Titan | Breakthrough TNBC Treatment Advances: FDA to Review Novel Radiopharmaceutical Trial Protocol - Stock Titan |
| 2023-03-09 | -12.0% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2025-10-06 | -11.2% | legal | SEC EDGAR | CLRB 8-K: 7.01, 8.01 (SEC Filing) |
| 2024-01-25 | +11.2% | legal | SEC EDGAR | CLRB 8-K: 8.01 (SEC Filing) |
| 2025-04-30 | -11.1% | news | GuruFocus | Cellectar Biosciences (CLRB) Considers Strategic Options to Enha - GuruFocus |
| 2024-11-15 | -11.1% | earnings | Seeking Alpha | Cellectar Biosciences Q3 2024 Earnings Preview |
| 2024-11-15 | -11.1% | legal | SEC EDGAR | CLRB 8-K: 8.01 and (SEC Filing) |
| 2022-09-22 | -10.5% | legal | SEC EDGAR | CLRB 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-11-29 | +10.4% | legal | SEC EDGAR | CLRB 8-K: 8.01 (SEC Filing) |
| 2022-05-10 | -10.0% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2026-04-14 | +8.9% | news | GlobeNewswire | Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) |
| 2023-11-02 | +8.5% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2025-05-13 | -8.5% | earnings | Seeking Alpha | Cellectar signals Q3 EMA decision for conditional iopofosine approval while advancing pipeline and exploring strategic alternatives |
| 2025-05-13 | -8.5% | earnings | Seeking Alpha | Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript |
| 2025-05-13 | -8.5% | earnings | Seeking Alpha | Cellectar Biosciences GAAP EPS of -$0.14 beats by $0.02 |
| 2025-05-13 | -8.5% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2025-08-16 | +8.3% | analyst | The Globe and Mail | Oppenheimer Sticks to Its Hold Rating for Cellectar Biosciences (CLRB) - The Globe and Mail |
| 2024-05-14 | +8.1% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2024-01-09 | +8.0% | legal | SEC EDGAR | CLRB 8-K: 8.01 and (SEC Filing) |
| 2025-05-12 | -8.0% | earnings | Seeking Alpha | Cellectar Biosciences Q1 2025 Earnings Preview |
| 2022-11-03 | -7.7% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2023-08-14 | +7.5% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2023-09-08 | -6.5% | legal | SEC EDGAR | CLRB 8-K: 1.01, 3.02, 5.03 (SEC Filing) |
| 2022-08-05 | +6.3% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2022-08-10 | +6.0% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Cellectar Biosciences (CLRB) - Zacks Investment Research |
| 2025-05-01 | +5.8% | legal | SEC EDGAR | CLRB 8-K: 8.01 and (SEC Filing) |
| 2024-08-13 | +5.6% | earnings | Seeking Alpha | Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript |
| 2024-08-13 | +5.6% | earnings | Seeking Alpha | Cellectar Biosciences reports Q2 results |
| 2024-08-13 | +5.6% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2026-02-17 | -5.2% | news | GlobeNewswire | Cellectar Biosciences Expands Global Intellectual Property Estate |
| 2022-06-07 | +5.0% | legal | SEC EDGAR | CLRB 8-K: 8.01 (SEC Filing) |
| 2021-08-09 | -4.9% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2026-04-23 | -4.6% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | CLRB (Cellectar Biosciences Inc.) reports narrower than expected Q4 2025 loss, yet shares drop nearly 3 percent. - High Interest Stocks - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2021-11-02 | +4.5% | legal | SEC EDGAR | CLRB 8-K: 3.01, 5.02 (SEC Filing) |
| 2025-08-13 | -4.5% | earnings | Seeking Alpha | Cellectar Biosciences Q2 2025 Earnings Preview |
| 2023-05-04 | -4.4% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2023-01-01 | -4.3% | analyst | TradingView | CLRB Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-02-25 | +4.2% | news | GlobeNewswire | Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 |
| 2023-06-29 | +3.8% | legal | SEC EDGAR | CLRB 8-K: 8.01 and (SEC Filing) |
| 2023-06-29 | +3.8% | legal | SEC EDGAR | CLRB 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-10-10 | +3.7% | legal | SEC EDGAR | CLRB 8-K: 1.01, 2.02, 3.02, 3.03, 8.01 (SEC Filing) |
| 2022-12-02 | +3.6% | legal | SEC EDGAR | CLRB 8-K: 1.01, 5.03 (SEC Filing) |
| 2023-01-04 | +3.4% | legal | SEC EDGAR | CLRB 8-K: 1.01 and 2.03 (SEC Filing) |
| 2021-05-03 | -3.4% | legal | SEC EDGAR | CLRB 8-K: 5.02 (SEC Filing) |
| 2024-07-22 | -3.3% | legal | SEC EDGAR | CLRB 8-K: 1.01, 3.02, 3.03, 7.01 (SEC Filing) |
| 2026-03-04 | +3.2% | earnings | Moby | Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary |
| 2026-03-04 | +3.2% | earnings | Motley Fool | Cellectar (CLRB) Q4 2025 Earnings Call Transcript |
| 2026-03-04 | +3.2% | news | GlobeNewswire | Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates |
| 2026-03-04 | +3.2% | earnings | Seeking Alpha | Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript |
| 2026-03-04 | +3.2% | earnings | Seeking Alpha | Cellectar Biosciences GAAP EPS of -$8.35 |
| 2026-03-04 | +3.2% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2021-06-24 | +3.1% | legal | SEC EDGAR | CLRB 8-K: 5.02, 5.07, 7.01 (SEC Filing) |
| 2024-08-23 | +3.0% | news | Seeking Alpha | Cellectar receives delinquency notification letter from Nasdaq, co to restate financial statements |
| 2024-08-12 | +3.0% | earnings | Seeking Alpha | Cellectar Biosciences Q2 2024 Earnings Preview |
| 2021-11-08 | -2.9% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2022-10-25 | -2.8% | legal | SEC EDGAR | CLRB 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2023-10-27 | -2.8% | legal | SEC EDGAR | CLRB 8-K: 5.03, 5.07, 8.01 (SEC Filing) |
| 2026-04-21 | -2.7% | news | GlobeNewswire | Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 |
| 2026-04-21 | -2.7% | news | Stock Titan | Cellectar takes cancer-drug data to ASCO for patients with no approved therapy - Stock Titan |
| 2024-03-27 | +2.6% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2022-06-27 | +2.4% | legal | SEC EDGAR | CLRB 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-03-12 | -2.4% | M&A | Investing.com | Cellectar Biosciences COO acquires $8,400 in stock - Investing.com |
| 2026-04-22 | -2.4% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | CLRB (Cellectar Biosciences Inc.) reports narrower than expected Q4 2025 loss, yet shares drop nearly 3 percent. - Cổng thông tin điện tử Tỉnh Sơn La |
| 2023-06-20 | -2.4% | legal | SEC EDGAR | CLRB 8-K: 8.01 (SEC Filing) |
| 2022-09-13 | -2.0% | legal | SEC EDGAR | CLRB 8-K: 8.01 and (SEC Filing) |
| 2025-06-26 | -1.8% | legal | SEC EDGAR | CLRB 8-K: 8.01 (SEC Filing) |
| 2022-03-15 | +1.8% | legal | SEC EDGAR | CLRB 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-08-14 | -1.6% | earnings | Seeking Alpha | Cellectar signals NDA submission for iopofosine I-131 in WM by early 2026 amid accelerated approval focus |
| 2025-08-14 | -1.6% | earnings | Seeking Alpha | Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript |
| 2025-08-14 | -1.6% | earnings | Seeking Alpha | Cellectar Biosciences GAAP EPS of -$3.39 beats by $0.31 |
| 2025-08-14 | -1.6% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2025-07-15 | +1.3% | analyst | Yahoo Finance | All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - Yahoo Finance |
| 2023-08-09 | +1.2% | news | CoinCodex | Cellectar BioSciences (CLRB) Dividend History, Date, and Yield - CoinCodex |
| 2024-11-11 | +1.2% | earnings | Stock Titan | Cellectar Biosciences (CLRB) Sets Q3 2024 Earnings Call for Nov 18 - Stock Titan |
| 2021-05-10 | -1.1% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2024-07-24 | -0.9% | analyst | Seeking Alpha | Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript |
| 2025-03-13 | -0.7% | earnings | Seeking Alpha | Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript |
| 2025-03-13 | -0.7% | news | Seeking Alpha | Cellectar Biosciences reports FY results |
| 2025-03-13 | -0.7% | legal | SEC EDGAR | CLRB 8-K: 2.02 and (SEC Filing) |
| 2025-03-13 | -0.7% | legal | Stock Titan | Cellectar's Breakthrough: 83.6% Response Rate Puts FDA Fast Track Within Reach - Stock Titan |
| 2025-03-13 | -0.7% | earnings | qz.com | Cellectar Biosciences Inc. (CLRB) reports earnings - qz.com |
| 2024-11-01 | -0.7% | news | Seeking Alpha | Cellectar Biosciences regains compliance with Nasdaq |
| 2024-11-01 | -0.7% | legal | SEC EDGAR | CLRB 8-K: 8.01 and (SEC Filing) |
| 2025-06-01 | -0.6% | news | Intellectia AI | CLRB Forecast — Price Prediction for 2026. Should I Buy CLRB? - Intellectia AI |
| 2024-06-25 | +0.5% | legal | SEC EDGAR | CLRB 8-K: 1.01 and 2.03 (SEC Filing) |
| 2024-12-14 | -0.4% | earnings | Seeking Alpha | Micron Technology, Nike Lead Companies That Report As Earnings Season Continues To Slow |
| 2024-05-11 | -0.3% | earnings | MarketBeat | Cellectar Biosciences (CLRB) Stock Forecast and Price Target 2026 $CLRB - MarketBeat |
| 2026-03-06 | -0.3% | news | Cantech Letter | Should you sell your Cellectar Biosciences stock? - Cantech Letter |
| 2022-02-25 | +0.1% | legal | SEC EDGAR | CLRB 8-K: 5.02 and (SEC Filing) |
| 2026-04-24 | — | news | MEXC Exchange | CLRB Price Today: Cellectar Biosciences INC NEW Stock Price, Quote & Chart | MEXC - MEXC Exchange |